[1]

LI Fei, DING Huiqin, CHEN Mengjing. Isonlosinine induces autophagy of PC9 cells by ERK signaling pathway in lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1235-1240.

[2]

MAO Jun, RONG Yu, LI Yangen, XIONG Dengxi, ZHAO Peng, ZHA Zhengjiang. Effect and safety of flurbiprofen axetil in the analgesic treatment of patients with craniocerebral injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1056-1060.

[3]

HOU Qiong, LIU Fei, CHEN Chuanrong. Immunotherapy combined with anti-angiogenic drugs and chemotherapy in negative driver gene and advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 775-779.

[4]

[5]

ZHANG Kexin, JIA Wenjing, CUI Jiawen, AO Luyao, ZHOU Fang, WANG Guangji, LIU Jiali. Advances in the research and clinical application of the third generation EGFR TKIs in the treatment of non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1016-1030.

[6]

WANG Lin, LI Chongyang, LI Shuaihu, GAO Shenghan, XU Tian, LI Fei. Research progress on pathogenic fusion gene in lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 877-885.

[7]

CUI Hua, YAN Hongxia, YIN Mei. Effects of down-regulating lncRNA LINC00176 on cisplatin resistance and autophagy in lung cancer A549/DDP cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 616-623.

[8]

XIE Rongrong, CHEN Zhi, YANG Yu, XIE Raoying, LI Pingping, SUN Shuangshuang, CHEN Wenjun. Treatment strategies of FGFR molecular alterations in lung squamous cell carcinoma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 196-203.

[9]

PEI Qinghua, SUN Jianli. Research progress of Osimertinib acquired resistance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 105-112.

[10]

WEI Weitian, CHEN Sheng, WANG Liang, ZENG Jian. Breviscapine induced the apoptosis of non-small cell lung cancer A549 cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 618-624.

[11]

ZHU Linjia, YUAN Shaofei, SHANGGUAN Zongxiao, CI Xiao, ZHAO Renguo, LI Yuping. Ultrasound-microbubbles mediated microRNA-449a inhibits lung cancer cell growth via the regulation of Notch1 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(12): 1385-1393.

[12]

YANG Ke, LI Junling, DU Bin, TIAN Zhongqiu, JING Xiujuan. Single-arm,one-center, exploratory clinical trial of albumin-bound paclitaxel second and more line therapy for advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(11): 1281-1286.

[13]

PAN Huan, ZHOU Yuling, QI Weibo, SHEN Hui, JIN Jing, SHEN Jianfen, MA Xingjie, XU Yufen. Expression and function of transmembrane protein 106A in lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 529-534.

[14]

WANG Haili, GONG Tianxiao, ZHOU Shixia, MEI Jiazhuan, ZHANG Zhongmian. Efficacy and safety of third-line treatment with mesylate apatinib in patients with advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 567-572.

[15]

YUAN Jing, SUN Jingxue, HUANG Daiqiang, YUAN Lin, DING Dengfeng. Effects of low dose dexmedetomidine combined with ulinastatin on immune function and stress response in patients with lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 83-88.

PDF (PC)

Knowledge